Survival among women with triple receptor-negative breast cancer and brain metastases

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 621-627

  Dawood, Shaheenah ^a,b   Broglio, K ^a   Esteva, F J ^a   Yang, W ^a   Kau, S W ^a   Islam, R ^a   Albarracin, C ^a   Yu, T K ^a   Green, M ^a   Hortobagyi, G N ^a   Gonzalez Angulo, A M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

Brain metastases; Breast cancer; Triple negative

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; NEUROSURGERY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 63549116437     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn682     Document Type: Article

References (26)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
2. Sorlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-2675.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
4. Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 2005; 23: 7350-7360.
5. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13(8): 2329-2334.
6. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24(36): 5652-5657.
7. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22(17): 3608-3617.
8. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349-2354.
9. Patanaphan V, Salazar OM, Risco R. Breast cancer: Metastatic patterns and their prognosis. South Med J 1988; 81: 1109-1112.
10. DiStefano A, Yap HY, Hortobagyi GN et al. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44: 1913-1918.
11. Engel J, EcKel R, Aydemir U et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1186-1195.
12. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-944.
13. Hicks DG, Short SM, Prescott NL et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK 5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-1104.
14. Tham YL, Sexton K, Kramer R et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.
15. Stemmler HJ, Kahlert S, Siekiera W et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15: 219-225.
16. Samaan NA, Buzdar AU, Aldinger KA et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981; 47: 554-560.
17. Singletary SE, Allred C, Ashley P et al. Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83: 803-819.
18. The World Health Organization Histological Typing of Breast Tumors - Second Edition. The World Organization. Am J Clin Pathol 1982; 78: 806-816.
19. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957; 105: 97-102.
20. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2006; http://www.R-project.org (April 2008, date last accessed).
21. Gray B. cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.1-5. 2004 http://www.r-project.org, http://biowww.dfci.harvard.edu/~gray (April 2008, date last accessed).
22. Nam B-H, Kim SY, Han HS et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10: R20 (April 2008, dater last accessed).
23. Hines SL, Vallow LA, Tan WW et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008; 19(5): 1561-1565.
24. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19(7): 1242-1248.
25. Yonemori K, Tsuta K, Shimizu C et al. Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol 2008; 70(20): 223-228.
26. Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68(9): 3108-3114.